ScholarIQanswers from OpenAlex
Odense University Hospital
InstitutionResearch output, impact & collaborations
Odense University Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Odense University Hospital?
ScholarIQrecord summary
Odense University Hospital is a research organisation in Odense, DK. OpenAlex records 41,082 works and 2,779,653 citations for it. 7,035 researchers list it as their most recent affiliation.
How many works does Odense University Hospital have?
ScholarIQindexed works
Odense University Hospital has 41,082 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Odense University Hospital have?
ScholarIQcitation count
Odense University Hospital has 2,779,653 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Odense University Hospital?
ScholarIQresearcher count
Odense University Hospital has 7,035 researchers in the ScholarIQ index.
What is the average h-index at Odense University Hospital?
ScholarIQavg h-index
Odense University Hospital has an average h-index of 60.3 in OpenAlex.
What is the ROR of Odense University Hospital?
ScholarIQror
The ROR for Odense University Hospital is on the source record.
What is the OpenAlex record for Odense University Hospital?
ScholarIQopenalex
The OpenAlex for Odense University Hospital is on the source record.
What is the Wikidata of Odense University Hospital?
ScholarIQwikidata
The Wikidata for Odense University Hospital is on the source record.
Who are the most-cited researchers behind Odense University Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Odense University Hospital?
ScholarIQmost cited works
Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms
Anders Wanhainen, Fabio Verzini, Isabelle Van Herzeele, Éric Allaire, Matthew J. Bown, Tina Cohnert, Florian Dick, Joost A. van Herwaarden, Christos D. Karkos, Mark J.W. Koelemay, Tilo Kölbel, Ian Loftus, Kevin Mani, Germano Melissano, Janet T. Powell, Zoltán Szeberin, Gert J. de Borst, Nabil Chakfé, Sebastian Debus, R.J. Hinchliffe, Stavros Kakkos, Igor Koncar, Philippe Kolh, Jes S. Lindholt, Melina de Vega, Frank Vermassen, Document reviewers, Martin Björck, Stephen Cheng, Ronald L. Dalman, Lazar Davidović, Konstantinos Donas, Jonothan Earnshaw, Hans‐Henning Eckstein, Jonathan Golledge, Stéphan Haulon, Tara M. Mastracci, Ross Naylor, Jean‐Baptiste Ricco, Hence J.M. Verhagen
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Torsten Zuberbier, Werner Aberer, Riccardo Asero, Amir Hamzah Abdul Latiff, Donald R Baker, Barbara Ballmer‐Weber, Jonathan A. Bernstein, Carsten Bindslev‐Jensen, Zenon Brzoza, Roberta Buense Bedrikow, Giorgio Walter Canonica, Martin K. Church, Timothy Craig, I V Danilycheva, Corinna Dressler, Luís Felipe Ensina, Ana M. Giménez‐Arnau, Kiran Godse, Margarida Gonçalo, Clive Grattan, Jean‐Louis Hébert, Michihiro Hide, Allen P. Kaplan, Alexander Kapp, Constance H. Katelaris, Emek Kocatürk, Kanokvalai Kulthanan, Désirée Larenas‐Linnemann, T.A. Leslie, Markus Magerl, P. Mathelier‐Fusade, Raisa Meshkova, Martin Metz, Alexander Nast, Eustachio Nettis, Hanneke Oude‐Elberink, Stefanie Rosumeck, Sarbjit S. Saini, Mario Sánchez‐Borges, Peter Schmid‐Grendelmeier, Petra Staubach, Gordon Sussman, Elias Toubi, Gino Antonio Vena, Christian Vestergaard, Bettina Wedi, Ricardo Niklas Werner, Zuotao Zhao, Marcus Maurer, Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
Antonella Muraro, Thomas Werfel, Karin Hoffmann‐Sommergruber, Graham Roberts, Kirsten Beyer, Carsten Bindslev‐Jensen, Victória Cardona, A. E. J. Dubois, George DuToit, Philippe Eigenmann, Montserrat Fernández‐Rivas, Susanne Halken, Lennart Hickstein, Arne Høst, Edward F. Knol, Gideon Lack, M. J. Marchisotto, B. Niggemann, Bright I. Nwaru, Nikolaos G. Papadopoulos, Lars K. Poulsen, Alexandra F. Santos, Isabel Skypala, Alain Schoepfer, Ronald van Ree, Carina Venter, Margitta Worm, Berber Vlieg‐Boerstra, Sukhmeet S. Panesar, Debra de Silva, Karla Soares‐Weiser, Aziz Sheikh, Barbara Ballmer‐Weber, Caroline Nilsson, Nicolette W. de Jong, Cezmi A. Akdiş, the EAACI Food Allergy and Anaphylaxis Guidelines Group
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
How much of the research on Odense University Hospital is open access?
ScholarIQopen access share
92%OPEN ACCESS